Berberine is a potential alternative for metformin with good regulatory effect on lipids in treating metabolic diseases

• Published in: Biomedicine & pharmacotherapy Vol. 163; p. 114754
• Main Authors: Guo, Hui-Hui, Shen, Hao-Ran, Wang, Lu-Lu, Luo, Zhi-Gang, Zhang, Jin-Lan, Zhang, Hong-Juan, Gao, Tian-Le, Han, Yan-Xing, Jiang, Jian-Dong
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01.07.2023
• Subjects: Animals; Bacteria-derived metabolites; Berberine; Berberine - pharmacology; Berberine - therapeutic use; Cricetinae; Gut barrier; Gut microbiota; Hyperlipidemias - drug therapy; Lipids - therapeutic use; Metabolic-related disorders; Metformin; Metformin - pharmacology; Metformin - therapeutic use; Mice; Obesity - drug therapy; TMAO; Gut microbiota; Bacteria-derived metabolites; T2DM; NAFLD; HFD; ALT; PCSK9; CHO; LPS; CEs; BBR; BAs; LDLR; Berberine; LDL-c; InsR; TMA; SREBP-1c; PPARγ; Metabolic-related disorders; TG; AB-PAS; Gut barrier; AMPK; SCFAs; Metformin; MTF

Metformin (MTF) and berberine (BBR) share several therapeutic benefits in treating metabolic-related disorders. However, as the two agents have very different chemical structure and bioavailability in oral route, the goal of this study is to learn their characteristics in treating metabolic disorder...